Matches in SemOpenAlex for { <https://semopenalex.org/work/W2169631718> ?p ?o ?g. }
- W2169631718 endingPage "1217" @default.
- W2169631718 startingPage "1206" @default.
- W2169631718 abstract "Available treatments for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B are associated with poor sustained responses. As a result, nucleoside and nucleotide analogues are typically continued indefinitely, a strategy associated with the risk of resistance and unknown long-term safety implications.We compared the efficacy and safety of peginterferon alfa-2a (180 microg once weekly) plus placebo, peginterferon alfa-2a plus lamivudine (100 mg daily), and lamivudine alone in 177, 179, and 181 patients with HBeAg-negative chronic hepatitis B, respectively. Patients were treated for 48 weeks and followed for an additional 24 weeks.After 24 weeks of follow-up, the percentage of patients with normalization of alanine aminotransferase levels or hepatitis B virus (HBV) DNA levels below 20,000 copies per milliliter was significantly higher with peginterferon alfa-2a monotherapy (59 percent and 43 percent, respectively) and peginterferon alfa-2a plus lamivudine (60 percent and 44 percent) than with lamivudine monotherapy (44 percent, P=0.004 and P=0.003, respectively; and 29 percent, P=0.007 and P=0.003, respectively). Rates of sustained suppression of HBV DNA to below 400 copies per milliliter were 19 percent with peginterferon alfa-2a monotherapy, 20 percent with combination therapy, and 7 percent with lamivudine alone (P<0.001 for both comparisons with lamivudine alone). Loss of hepatitis B surface antigen occurred in 12 patients in the peginterferon groups, as compared with 0 patients in the group given lamivudine alone. Adverse events, including pyrexia, fatigue, myalgia, and headache, were less frequent with lamivudine monotherapy than with peginterferon alfa-2a monotherapy or combination therapy.Patients with HBeAg-negative chronic hepatitis B had significantly higher rates of response, sustained for 24 weeks after the cessation of therapy, with peginterferon alfa-2a than with lamivudine. The addition of lamivudine to peginterferon alfa-2a did not improve post-therapy response rates." @default.
- W2169631718 created "2016-06-24" @default.
- W2169631718 creator A5008075213 @default.
- W2169631718 creator A5012052658 @default.
- W2169631718 creator A5013246678 @default.
- W2169631718 creator A5020478633 @default.
- W2169631718 creator A5029473963 @default.
- W2169631718 creator A5042037558 @default.
- W2169631718 creator A5045166316 @default.
- W2169631718 creator A5049183697 @default.
- W2169631718 creator A5051190667 @default.
- W2169631718 creator A5061689613 @default.
- W2169631718 creator A5066066723 @default.
- W2169631718 creator A5068581809 @default.
- W2169631718 creator A5081861980 @default.
- W2169631718 creator A5087679429 @default.
- W2169631718 creator A5088602858 @default.
- W2169631718 date "2004-09-16" @default.
- W2169631718 modified "2023-10-06" @default.
- W2169631718 title "Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B" @default.
- W2169631718 cites W1517300131 @default.
- W2169631718 cites W1594706749 @default.
- W2169631718 cites W1972774048 @default.
- W2169631718 cites W1972979898 @default.
- W2169631718 cites W1981900811 @default.
- W2169631718 cites W1983757435 @default.
- W2169631718 cites W1987119060 @default.
- W2169631718 cites W1992194872 @default.
- W2169631718 cites W1999263104 @default.
- W2169631718 cites W2012090731 @default.
- W2169631718 cites W2027545702 @default.
- W2169631718 cites W2047030504 @default.
- W2169631718 cites W2052968140 @default.
- W2169631718 cites W2062899552 @default.
- W2169631718 cites W2063846412 @default.
- W2169631718 cites W2071291950 @default.
- W2169631718 cites W2084720260 @default.
- W2169631718 cites W2094608386 @default.
- W2169631718 cites W2095541672 @default.
- W2169631718 cites W2097754581 @default.
- W2169631718 cites W2112145547 @default.
- W2169631718 cites W2119612879 @default.
- W2169631718 cites W2132254613 @default.
- W2169631718 cites W2133291642 @default.
- W2169631718 cites W2141249273 @default.
- W2169631718 cites W2149337924 @default.
- W2169631718 cites W2149836081 @default.
- W2169631718 cites W2161280033 @default.
- W2169631718 cites W2332630894 @default.
- W2169631718 cites W3216648493 @default.
- W2169631718 cites W4232116493 @default.
- W2169631718 cites W4235965176 @default.
- W2169631718 cites W4367435828 @default.
- W2169631718 doi "https://doi.org/10.1056/nejmoa040431" @default.
- W2169631718 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15371578" @default.
- W2169631718 hasPublicationYear "2004" @default.
- W2169631718 type Work @default.
- W2169631718 sameAs 2169631718 @default.
- W2169631718 citedByCount "1051" @default.
- W2169631718 countsByYear W21696317182012 @default.
- W2169631718 countsByYear W21696317182013 @default.
- W2169631718 countsByYear W21696317182014 @default.
- W2169631718 countsByYear W21696317182015 @default.
- W2169631718 countsByYear W21696317182016 @default.
- W2169631718 countsByYear W21696317182017 @default.
- W2169631718 countsByYear W21696317182018 @default.
- W2169631718 countsByYear W21696317182019 @default.
- W2169631718 countsByYear W21696317182020 @default.
- W2169631718 countsByYear W21696317182021 @default.
- W2169631718 countsByYear W21696317182022 @default.
- W2169631718 countsByYear W21696317182023 @default.
- W2169631718 crossrefType "journal-article" @default.
- W2169631718 hasAuthorship W2169631718A5008075213 @default.
- W2169631718 hasAuthorship W2169631718A5012052658 @default.
- W2169631718 hasAuthorship W2169631718A5013246678 @default.
- W2169631718 hasAuthorship W2169631718A5020478633 @default.
- W2169631718 hasAuthorship W2169631718A5029473963 @default.
- W2169631718 hasAuthorship W2169631718A5042037558 @default.
- W2169631718 hasAuthorship W2169631718A5045166316 @default.
- W2169631718 hasAuthorship W2169631718A5049183697 @default.
- W2169631718 hasAuthorship W2169631718A5051190667 @default.
- W2169631718 hasAuthorship W2169631718A5061689613 @default.
- W2169631718 hasAuthorship W2169631718A5066066723 @default.
- W2169631718 hasAuthorship W2169631718A5068581809 @default.
- W2169631718 hasAuthorship W2169631718A5081861980 @default.
- W2169631718 hasAuthorship W2169631718A5087679429 @default.
- W2169631718 hasAuthorship W2169631718A5088602858 @default.
- W2169631718 hasBestOaLocation W21696317181 @default.
- W2169631718 hasConcept C126322002 @default.
- W2169631718 hasConcept C142724271 @default.
- W2169631718 hasConcept C203014093 @default.
- W2169631718 hasConcept C204787440 @default.
- W2169631718 hasConcept C2522874641 @default.
- W2169631718 hasConcept C27081682 @default.
- W2169631718 hasConcept C2775940106 @default.
- W2169631718 hasConcept C2776235749 @default.
- W2169631718 hasConcept C2776999253 @default.
- W2169631718 hasConcept C2777382497 @default.